Valley Brook Capital Group Inc. Sells 88 Shares of AbbVie Inc. (NYSE:ABBV)

Valley Brook Capital Group Inc. cut its position in AbbVie Inc. (NYSE:ABBV) by 0.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 22,699 shares of the company’s stock after selling 88 shares during the period. AbbVie makes up 3.0% of Valley Brook Capital Group Inc.’s holdings, making the stock its 6th largest position. Valley Brook Capital Group Inc.’s holdings in AbbVie were worth $4,034,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Capital Advisors Inc. OK boosted its position in AbbVie by 1.6% during the fourth quarter. Capital Advisors Inc. OK now owns 335,011 shares of the company’s stock worth $59,531,000 after purchasing an additional 5,119 shares in the last quarter. Certuity LLC boosted its position in AbbVie by 82.8% during the fourth quarter. Certuity LLC now owns 11,964 shares of the company’s stock worth $2,126,000 after purchasing an additional 5,418 shares in the last quarter. Community Financial Services Group LLC boosted its position in AbbVie by 9.5% during the fourth quarter. Community Financial Services Group LLC now owns 2,687 shares of the company’s stock worth $477,000 after purchasing an additional 233 shares in the last quarter. Montz Harcus Wealth Management LLC boosted its position in AbbVie by 12.5% during the fourth quarter. Montz Harcus Wealth Management LLC now owns 2,204 shares of the company’s stock worth $392,000 after purchasing an additional 245 shares in the last quarter. Finally, Leavell Investment Management Inc. boosted its position in AbbVie by 0.8% during the fourth quarter. Leavell Investment Management Inc. now owns 79,674 shares of the company’s stock worth $14,158,000 after purchasing an additional 629 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity at AbbVie

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $172.24, for a total transaction of $310,032.00. Following the transaction, the senior vice president now owns 6,983 shares of the company’s stock, valued at $1,202,751.92. This represents a 20.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 0.25% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Guggenheim increased their price target on AbbVie from $212.00 to $214.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. UBS Group increased their price target on AbbVie from $181.00 to $190.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. Wells Fargo & Company raised their target price on AbbVie from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Bank of America restated a “neutral” rating and issued a $191.00 target price on shares of AbbVie in a research report on Tuesday, December 10th. Finally, Daiwa America downgraded AbbVie from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 5th. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average price target of $208.35.

AbbVie Price Performance

ABBV stock opened at $191.81 on Wednesday. AbbVie Inc. has a 1 year low of $153.58 and a 1 year high of $207.32. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.54 and a current ratio of 0.65. The stock’s 50 day moving average price is $177.71 and its 200 day moving average price is $185.81. The firm has a market cap of $338.96 billion, a P/E ratio of 79.92, a PEG ratio of 1.53 and a beta of 0.58.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 257.91%. During the same period in the previous year, the business posted $2.79 earnings per share. On average, sell-side analysts expect that AbbVie Inc. will post 12.32 earnings per share for the current fiscal year.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.